Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.

Publication date: Jul 11, 2023

As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, and short-term durability of binding and pseudovirus-neutralizing antibody (PsVNA) responses following a single booster dose of NVX-CoV2373 in adults primed with either Ad26. COV2. S, mRNA-1273, or BNT162b2 vaccines. NVX-CoV2373 as a heterologous booster was immunogenic and associated with no safety concerns through Day 91. Fold-rises in PsVNA titers from baseline (Day 1) to Day 29 were highest for prototypic D614G variant and lowest for more recent Omicron sub-lineages BQ. 1.1 and XBB. 1. Peak humoral responses against all SARS-CoV-2 variants were lower in those primed with Ad26. COV2. S than with mRNA vaccines. Prior SARS CoV-2 infection was associated with substantially higher baseline PsVNA titers, which remained elevated relative to previously uninfected participants through Day 91. These data support the use of heterologous protein-based booster vaccines as an acceptable alternative to mRNA or adenoviral-based COVID-19 booster vaccines. This trial was conducted under ClinicalTrials. gov: NCT04889209.

Open Access PDF

Concepts Keywords
Clinicaltrials Ad26
Humoral Booster
Nct04889209 Cov
Vaccines Cov2


Type Source Name
disease VO NVX-CoV2373
disease MESH COVID-19
disease VO dose
disease VO Ad26.COV2.S
disease MESH infection
drug DRUGBANK Angelica archangelica root
disease VO vaccination
disease MESH complications
disease VO immunization
disease VO vaccine
disease MESH emergency
disease VO population
disease VO USA
disease MESH Infectious Diseases
pathway REACTOME Infectious disease
disease IDO infectious disease
disease MESH AIDS
disease MESH Allergy
drug DRUGBANK Coenzyme M
disease IDO history
disease VO adverse event
disease VO injection
disease MESH lymphadenopathy
disease IDO blood
disease MESH stroke
disease MESH seizure
disease VO primary vaccination
disease IDO assay
disease VO age
disease VO vaccine dose
disease VO boost vaccination

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *